Published in Br J Anaesth on September 01, 2002
Dose estimation for children. Br J Clin Pharmacol (2003) 1.24
Modelling approaches to dose estimation in children. Br J Clin Pharmacol (2005) 1.21
Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach. Br J Pharmacol (2007) 0.81
Scaling of pharmacokinetics across paediatric populations: the lack of interpolative power of allometric models. Br J Clin Pharmacol (2012) 0.80
The interplay between drugs and the kidney in premature neonates. Pediatr Nephrol (2013) 0.78
Modelling acute tolerance to the EEG effect of two benzodiazepines. Br J Clin Pharmacol (2004) 0.77
Preventing Emergence Agitation Using Ancillary Drugs with Sevoflurane for Pediatric Anesthesia: A Network Meta-Analysis. Mol Neurobiol (2016) 0.75
A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet (1998) 3.33
Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists. Br J Clin Pharmacol (1981) 3.07
Oxidation phenotype--a major determinant of metoprolol metabolism and response. N Engl J Med (1982) 2.72
Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab Invest (1996) 2.47
Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection. J Chromatogr (1977) 2.43
Amiodarone pharmacokinetics. Am Heart J (1983) 2.42
Drosophila mitochondrial DNA: a novel gene order. Nucleic Acids Res (1982) 2.40
Mice homozygous for a targeted disruption of the proto-oncogene int-2 have developmental defects in the tail and inner ear. Development (1993) 2.39
Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol (1981) 2.38
Inhibition of oxidative drug metabolism by beta-adrenoceptor antagonists in related to their lipid solubility. Br J Clin Pharmacol (1981) 2.08
Origin and direction of replication in mitochondrial DNA molecules from Drosophila melanogaster. Proc Natl Acad Sci U S A (1978) 1.94
Binding of anilide-type local anesthetics in human plasma. I. Relationships between binding, physicochemical properties, and anesthetic activity. Anesthesiology (1970) 1.71
The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol (1992) 1.71
Polymorphic hydroxylation of debrisoquine. Lancet (1977) 1.69
Origin and direction of replication in mitochondrial DNA molecules from the genus Drosophila. Nucleic Acids Res (1980) 1.67
Plasma concentrations of local anaesthetics after interscalene brachial plexus block. Br J Anaesth (1977) 1.66
Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies. Br J Clin Pharmacol (1985) 1.64
Cloning of human purine-nucleoside phosphorylase cDNA sequences by complementation in Escherichia coli. Proc Natl Acad Sci U S A (1983) 1.61
Prevalence of liver disease in cystic fibrosis. Arch Dis Child (1991) 1.61
A six-year evaluation of methadone prescribing practices at a substance misuse treatment centre in the UK. J Clin Pharm Ther (2006) 1.58
Methylated bases in DNA from Paramecium aurelia. Biochim Biophys Acta (1974) 1.57
Increased hepatic copper concentration in Indian childhood cirrhosis. Lancet (1979) 1.54
Lack of effect of atenolol on antipyrine clearance. Br J Clin Pharmacol (1982) 1.51
Orcein-positive liver deposits in Indian childhood cirrhosis. Lancet (1978) 1.47
Clinical pharmacokinetics of local anaesthetics. Clin Pharmacokinet (1979) 1.47
Evaluation of an In Silico PBPK Post-Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine. CPT Pharmacometrics Syst Pharmacol (2013) 1.44
Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics (1996) 1.41
Gerontokinetics--a reappraisal. Br J Clin Pharmacol (1992) 1.41
Meperidine kinetics in man. Intravenous injection in surgical patients and volunteers. Clin Pharmacol Ther (1975) 1.39
Structure and replication of mitochondrial DNA from Paramecium aurelia. J Mol Biol (1975) 1.38
Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol (1997) 1.37
Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther (1988) 1.37
Measurement of the renal clearance of drugs. Br J Clin Pharmacol (1981) 1.35
Loss of Hox-A1 (Hox-1.6) function results in the reorganization of the murine hindbrain. Development (1993) 1.34
Development of a PCR probe test for identifying Pseudomonas aeruginosa and Pseudomonas (Burkholderia) cepacia. J Clin Pathol (1994) 1.33
Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation. Clin Pharmacol Ther (1986) 1.32
Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Clin Pharmacol (1986) 1.29
Lignocaine and indocyanine green kinetics in patients following myocardial infarction. Br J Clin Pharmacol (1980) 1.28
Human purine nucleoside phosphorylase cDNA sequence and genomic clone characterization. Nucleic Acids Res (1984) 1.26
Why hypertensive patients vary in their response to oral debrisoquine. Br Med J (1977) 1.25
3-Oxo-delta 4 bile acids in liver disease. Lancet (1988) 1.24
Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. Xenobiotica (2006) 1.24
Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab Dispos (1997) 1.23
Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers. Clin Pharmacol Ther (1983) 1.22
Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. Br J Clin Pharmacol (1999) 1.21
Mitochondrial DNA replication in Paramecium aurelia. Cross-linking of the initiation end. J Mol Biol (1977) 1.20
Functional intestinal obstruction due to deficiency of argyrophil neurones in the myenteric plexus. Familial syndrome presenting with short small bowel, malrotation, and pyloric hypertrophy. Arch Dis Child (1976) 1.19
Liver histology in the arthrogryposis multiplex congenita, renal dysfunction, and cholestasis (ARC) syndrome: report of three new cases and review. J Med Genet (1994) 1.17
The disposition of debrisoquine in hypertensive patients. Br J Clin Pharmacol (1978) 1.16
Isolation and characterization of Caenorhabditis elegans DNA sequences homologous to the v-abl oncogene. Proc Natl Acad Sci U S A (1986) 1.15
Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis. Br J Clin Pharmacol (2001) 1.15
Current clinical management of hepatic problems in cystic fibrosis. J R Soc Med (1986) 1.14
Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment. Xenobiotica (2007) 1.12
Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br J Clin Pharmacol (2003) 1.11
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease. J Pharmacol Exp Ther (1996) 1.11
Lactic acidosis during metformin treatment in an elderly diabetic patient with impaired renal function. Acta Med Scand (1981) 1.11
Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clin Endocrinol (Oxf) (2006) 1.10
Pharmacokinetic aspects of intravenous regional anesthesia. Anesthesiology (1971) 1.10
Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine. Drug Metab Dispos (2004) 1.10
Altered plasma drug binding in cancer: role of alpha 1-acid glycoprotein and albumin. Clin Pharmacol Ther (1982) 1.08
Meperidine and other basic drugs: general method for their determination in plasma. J Pharm Sci (1974) 1.08
Identification of a locus for progressive familial intrahepatic cholestasis PFIC2 on chromosome 2q24. Am J Hum Genet (1997) 1.08
Polymorphic metabolism of beta-adrenoceptor antagonists. Br J Clin Pharmacol (1984) 1.08
Targeted disruption of Hoxd-10 affects mouse hindlimb development. Development (1997) 1.08
Routine detection and identification in urine of stimulants and other drugs, some of which may be used to modify performance in sport. J Pharm Pharmacol (1967) 1.08
Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol (1985) 1.07
Systemic absorption of mepivacaine in commonly used regional block procedures. Anesthesiology (1972) 1.06
Features of carnitine palmitoyltransferase type I deficiency. J Inherit Metab Dis (2001) 1.05
Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica (2004) 1.05
Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6. J Biol Chem (1995) 1.05
Pharmacokinetics of local anaesthetics. Br J Anaesth (1986) 1.04
Pethidine revisited: plasma concentrations and effects after intramuscular injection. Br J Anaesth (1975) 1.04
Journal impact factors: a 'bioequivalence' issue? Br J Clin Pharmacol (2001) 1.04
Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers. Clin Endocrinol (Oxf) (2007) 1.04
Liver disease in India. Arch Dis Child (1982) 1.03
Effects of beta-adrenoceptor antagonists on the pharmacokinetics of lignocaine. Br J Clin Pharmacol (1984) 1.03
Copper associated childhood cirrhosis. Gut (1994) 1.02
Amiodarone pharmacokinetics. Br J Clin Pract Suppl (1986) 1.02
Premature eruption and macrodontia associated with insulin resistant diabetes and pineal hyperplasia. Report of two cases. Br Dent J (1976) 1.02
A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction. CPT Pharmacometrics Syst Pharmacol (2012) 1.02
The antitussive effect of dextromethorphan in relation to CYP2D6 activity. Br J Clin Pharmacol (1999) 1.01
Onchocerciasis in Sierra Leone. I. Studies on the prevalence and transmission at Gbaiima village. Trans R Soc Trop Med Hyg (1986) 1.01
The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations. Clin Pharmacokinet (1986) 1.00
The pharmacokinetics of methadone in healthy subjects and opiate users. Br J Clin Pharmacol (1997) 1.00
Medical students' compliance with simple administrative tasks and success in final examinations: retrospective cohort study. BMJ (2002) 0.99
Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--hypothesis testing. Br J Clin Pharmacol (1989) 0.99
Acebutolol in hypertension: relationships between drug concentration and effects. Eur J Clin Pharmacol (1978) 0.99
Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--histograms and probit plots. Br J Clin Pharmacol (1989) 0.99
Determination of metformin in biological samples. Br J Clin Pharmacol (1978) 0.98
In-vivo indices of enzyme activity: the effect of renal impairment on the assessment of CYP2D6 activity. Pharmacogenetics (1999) 0.96
Backtracking booze with Bayes--the retrospective interpretation of blood alcohol data. Br J Clin Pharmacol (1991) 0.95